Pier Giorgio Petronini

Pier Giorgio Petronini is a Full Professor of General Pathology at the University of Parma, leading the Experimental Oncology Laboratory within the Department of Medicine and Surgery. He has held research positions at the Pasteur Institute in Paris and serves on the Novartis Oncology Advisory Board, as Academic Editor for PLOS ONE, and reviewer for multiple journals.

• Scientific Director of Chiara Tassoni Association for Leukemia Research and Augusto per la Vita Association
• Member of Italian Society of Cancerology, European Association for Cancer Research, and American Society for Investigative Pathology

His research focuses on translational molecular oncology in lung, breast cancer, and malignant pleural mesothelioma, emphasizing preclinical therapeutic strategies. Key projects include targeting CDK4/6, EGFR, and PD-L1 pathways, with recent work on metabolic adaptations in drug-resistant cancers.

Selected publications highlight advancements in:

• CDK4/6-PI3K/AKT/mTOR combination therapy for TNBC
• FGFR2-MEK synergy in cancers of unknown primary
• PD-L1-STAT signaling in NSCLC angiogenesis

He coordinates grants from AIRC, Novartis, AstraZeneca, and Chiesi Farmaceutici, and holds patents for irreversible EGFR and MDR1 inhibitors.